Myriad Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Myriad Asset Management's VRTX Position: Q1 2022 in Review
Myriad Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 36% in Q1 2022, buying an estimated $878K and bringing the position to 14,100 shares worth $3.68M. The position accounts for 0.51% of the portfolio, ranked #22.
Myriad Asset Management first reported a position in VRTX in Q2 2021 and has held it in 4 quarters since. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.
- Myriad Asset Management held 14,100 shares of Vertex Pharmaceuticals worth $3.68M as of Q1 2022.
- Myriad Asset Management bought 3,700 Vertex Pharmaceuticals shares in Q1 2022, an estimated $878K.
- Vertex Pharmaceuticals made up 0.51% of Myriad Asset Management's portfolio in Q1 2022, its #22 holding.
- Myriad Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 4 quarters since.
- 1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.
Based on Myriad Asset Management's 13F filing for Q1 2022, filed 16 May 2022.